AU2019362389B2 - Compounds containing deuterium - Google Patents

Compounds containing deuterium Download PDF

Info

Publication number
AU2019362389B2
AU2019362389B2 AU2019362389A AU2019362389A AU2019362389B2 AU 2019362389 B2 AU2019362389 B2 AU 2019362389B2 AU 2019362389 A AU2019362389 A AU 2019362389A AU 2019362389 A AU2019362389 A AU 2019362389A AU 2019362389 B2 AU2019362389 B2 AU 2019362389B2
Authority
AU
Australia
Prior art keywords
melflufen
group
deuterium
iii
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019362389A
Other languages
English (en)
Other versions
AU2019362389A1 (en
Inventor
Fredrik Lehmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oncopeptides Innovation AB
Original Assignee
Oncopeptides Innovation AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1816998.7A external-priority patent/GB201816998D0/en
Priority claimed from GBGB1909695.7A external-priority patent/GB201909695D0/en
Application filed by Oncopeptides Innovation AB filed Critical Oncopeptides Innovation AB
Publication of AU2019362389A1 publication Critical patent/AU2019362389A1/en
Assigned to ONCOPEPTIDES INNOVATION AB reassignment ONCOPEPTIDES INNOVATION AB Request for Assignment Assignors: ONCOPEPTIDES AB
Application granted granted Critical
Publication of AU2019362389B2 publication Critical patent/AU2019362389B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F13/00Compounds containing elements of Groups 7 or 17 of the Periodic Table
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06191Dipeptides containing heteroatoms different from O, S, or N
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2019362389A 2018-10-18 2019-10-17 Compounds containing deuterium Active AU2019362389B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB1816998.7A GB201816998D0 (en) 2018-10-18 2018-10-18 Compounds
GB1816998.7 2018-10-18
GBGB1909695.7A GB201909695D0 (en) 2019-07-05 2019-07-05 Compounds
GB1909695.7 2019-07-05
PCT/EP2019/078250 WO2020079165A1 (en) 2018-10-18 2019-10-17 Compounds containing deuterium

Publications (2)

Publication Number Publication Date
AU2019362389A1 AU2019362389A1 (en) 2021-06-03
AU2019362389B2 true AU2019362389B2 (en) 2024-12-12

Family

ID=68290247

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019362389A Active AU2019362389B2 (en) 2018-10-18 2019-10-17 Compounds containing deuterium

Country Status (19)

Country Link
US (2) US12152087B2 (enExample)
EP (1) EP3866931B1 (enExample)
JP (2) JP7603199B2 (enExample)
KR (1) KR102848971B1 (enExample)
CN (1) CN112930214B (enExample)
AU (1) AU2019362389B2 (enExample)
BR (1) BR112021007060A2 (enExample)
CA (1) CA3116198A1 (enExample)
DK (1) DK3866931T3 (enExample)
ES (1) ES2942468T3 (enExample)
FI (1) FI3866931T3 (enExample)
HU (1) HUE061801T2 (enExample)
IL (1) IL282231B2 (enExample)
MA (1) MA53904A (enExample)
MX (1) MX2021004474A (enExample)
PL (1) PL3866931T3 (enExample)
SG (1) SG11202103726RA (enExample)
WO (1) WO2020079165A1 (enExample)
ZA (1) ZA202102492B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201905477D0 (en) * 2019-04-17 2019-05-29 Oncopeptides Ab Novel formulations
ES3034388T3 (en) * 2021-06-01 2025-08-18 Synthon Bv Process for making melflufen or a salt thereof
JP2024524552A (ja) 2021-07-08 2024-07-05 オンコペプティデス エービー 多発性骨髄腫の治療に使用するためのメルフルフェン
GB202109894D0 (en) 2021-07-08 2021-08-25 Oncopeptides Ab Novel treatments
GB202109896D0 (en) 2021-07-08 2021-08-25 Oncopeptides Ab Novel treatments
GB202109895D0 (en) 2021-07-08 2021-08-25 Oncopeptides Ab Novel treatments
GB202204171D0 (en) 2022-03-24 2022-05-11 Oncopeptides Ab Novel formulations
WO2026057823A1 (en) * 2024-09-13 2026-03-19 Oncopeptides Ab Bis-chloroethylamino derivatives for treating leukemia

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014065751A1 (en) * 2012-10-26 2014-05-01 Oncopeptides Ab Lyophilized preparations of melphalan flufenamide

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0002202D0 (sv) 2000-06-13 2000-06-13 Karolinska Innovations Ab New peptides
CA2972242A1 (en) 2008-09-18 2010-04-22 Auspex Pharmaceuticals, Inc. Benzoquinoline inhibitors of vesicular monoamine transporter 2
EP3351247A1 (en) 2010-06-01 2018-07-25 Auspex Pharmaceutical, Inc. Benzoquinolone inhibitors of vmat2
DK2701720T3 (en) * 2011-04-28 2017-10-09 Oncopeptides Ab Lyophilized preparation with cytotoxic dipeptides
EP4345100A3 (en) 2012-09-18 2024-04-10 Auspex Pharmaceuticals, Inc. Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
JP2016506957A (ja) 2013-01-31 2016-03-07 オースペックス・ファーマシューティカルズ・インコーポレイテッドAuspex Pharmaceuticals, Inc. Vmat2のベンゾキノロン阻害剤
ES2901752T3 (es) * 2013-02-05 2022-03-23 Teva Pharmaceuticals Int Gmbh Derivados de catecolamina enriquecidos con deuterio asimétrico de posición específica y medicamentos que comprenden dichos compuestos
WO2015084622A1 (en) 2013-12-03 2015-06-11 Auspex Pharmaceuticals, Inc. Methods of manufacturing benzoquinoline compounds
CN110229159B (zh) 2013-12-18 2021-08-24 康塞特医药品有限公司 卢索替尼的氘代衍生物
AU2016229949B2 (en) 2015-03-06 2021-04-08 Auspex Pharmaceuticals Llc Methods for the treatment of abnormal involuntary movement disorders
GB201507903D0 (en) 2015-05-08 2015-06-24 Oncopeptides Ab Process for preparation of nitrogen mustard derivatives
GB201521217D0 (en) * 2015-12-01 2016-01-13 Oncopeptides Ab Dosage regimens

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014065751A1 (en) * 2012-10-26 2014-05-01 Oncopeptides Ab Lyophilized preparations of melphalan flufenamide

Also Published As

Publication number Publication date
JP7603199B2 (ja) 2024-12-20
FI3866931T3 (fi) 2023-05-10
CN112930214A (zh) 2021-06-08
MX2021004474A (es) 2021-08-24
EP3866931B1 (en) 2023-02-15
IL282231A (en) 2021-05-31
MA53904A (fr) 2021-08-25
ES2942468T3 (es) 2023-06-01
KR102848971B1 (ko) 2025-08-21
US20250115637A1 (en) 2025-04-10
HUE061801T2 (hu) 2023-08-28
BR112021007060A2 (pt) 2021-07-20
KR20210078487A (ko) 2021-06-28
EP3866931A1 (en) 2021-08-25
IL282231B2 (en) 2025-07-01
US12152087B2 (en) 2024-11-26
JP2024150488A (ja) 2024-10-23
CN112930214B (zh) 2025-05-16
US20210388024A1 (en) 2021-12-16
AU2019362389A1 (en) 2021-06-03
WO2020079165A1 (en) 2020-04-23
IL282231B1 (en) 2025-03-01
JP2022512736A (ja) 2022-02-07
PL3866931T3 (pl) 2023-06-19
DK3866931T3 (da) 2023-04-24
CA3116198A1 (en) 2020-04-23
SG11202103726RA (en) 2021-05-28
ZA202102492B (en) 2024-04-24

Similar Documents

Publication Publication Date Title
AU2019362389B2 (en) Compounds containing deuterium
ES2920449T3 (es) Proceso de preparación de dos derivados de 4-{[(2s)-2-{4-[5-cloro-2-(1H-1,2,3-triazol-1-il)fenil]-5-metoxi-2-oxopiridin-1(2H)-il}butanoil]amino}-2-fluorobenzamida
JP5739446B2 (ja) ピロロ[2,3−d]ピリミジン化合物
ES2322678T3 (es) Derivado de depsipeptido, procedimiento para su produccion y nuevo intermedio del mismo.
WO2008075376A1 (en) Polymorphic forms of bortezomib and process for their preparation
EP3805237A1 (en) Synthesis and uses of peptide borate ester compound
AU2019351494A1 (en) Nitroxoline prodrug and use thereof
CA2168791A1 (en) Matrix metalloprotease inhibitors
RU2715233C2 (ru) Способ получения производных азотистого иприта
EP2896623A1 (en) CRYSTAL OF N-[2-({2-[(2S)-2-CYANOPYRROLIDIN-1-YL]-2- OXOETHYL}AMINO)-2-METHYLPROPYL]-2-METHYLPYRAZOLO[1,5-a]PYRIMIDINE-6-CARBOXAMIDE
HK40048606A (en) Compounds containing deuterium
HK40048606B (en) Compounds containing deuterium
CA2276598C (en) Method for synthesis of rhizoferrin
US6172256B1 (en) Chiral-β-amino acid compounds and derivatives thereof
EA045396B1 (ru) Соединения, содержащие дейтерий
EP3081556A1 (en) Amide compound and pharmaceutical comprising same
AU2024358622A1 (en) Process for making a kras g12c inhibitor
EP3778597A1 (en) Tetrahydroisoquinoline derivative, preparation method therefor and uses thereof
WO2009012656A1 (en) Inhibitors for matrix metalloproteinases, pharmaceutical compositions containing them and their uses

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: ONCOPEPTIDES INNOVATION AB

Free format text: FORMER APPLICANT(S): ONCOPEPTIDES AB

FGA Letters patent sealed or granted (standard patent)